Salute e Benessere

Hemostats Market Set to Attain Valuation of US$ 4,839 Million By 2033 Says…

This growth is driven by key factors such as the 26% rise in surgical procedures globally since 2014, with 375 million surgeries performed in 2024, and the increasing prevalence of trauma cases and military demand. Hemorrhage remains a leading cause of preventable deaths, accounting for 30% of combat fatalities and over 1.4 million road traffic deaths annually, creating a critical need for effective bleeding control solutions. Additionally, the rise of minimally invasive surgeries…

Swiss Medical Network joins the Mayo Clinic Care Network

For patients, the collaboration means advanced diagnoses and care services, specific executive health and check-up programs, and access to international experts from the Mayo Clinic Care Network without travelling abroad. Complex cancer cases can be presented to Mayo Clinic's multidisciplinary specialists. For patients, the collaboration means advanced diagnoses and care services, specific executive health and check-up programs, and access to international experts from the Mayo Clinic Care...

The Department of Health - Abu Dhabi and Sanofi Forge Strategic Alliance to…

In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Laurie Gery. Global Head of Business Development, Vaccines at Sanofi, the agreement was signed during the BIO International Convention in Boston, USA, by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Baptiste de Clarens, General Manager Greater Gulf, Vaccines at Sanofi. In the presence of H.E. Dr.Noura Khamis Al Ghaithi,...

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per June 16, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,532,753 shares, corresponding to 5.02% (previously 4.85%) of the total share capital attached to shares. The combined total of share capital...

VIRBAC: Paul Martingell is appointed chief executive officer of Virbac…

Virbac announces the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025. Paul Martingell, 45, is recognized as a leader who has demonstrated his ability to engage and inspire international teams, manage complexity, and create value for all stakeholders. He holds an MBA with distinction in Mergers and Acquisitions and is a Chartered Accountant in the United Kingdom. He has over 25 years of extensive international experience,...

Oxurion signs a letter of intent for the planned acquisition of a preclinical…

Leuven, BELGIUM – June 19, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces the signing of a letter of intent (LOI) to acquire 70% of the share capital of a company specialized in preclinical microbiology services for human and animal health, dermocosmetics, and nutraceuticals…

Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een…

Leuven, BELGIË – 19 juni 2025 – 8u30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt de ondertekening aan van een intentieverklaring (LOI) voor de overname van 70% van het aandelenkapitaal van een onderneming gespecialiseerd in preklinische microbiologische diensten voor humane en diergezondheid, dermocosmetica en nutraceutica…

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate…

Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement...

Elton John AIDS Foundation launches pilot schemes to accelerate access to…

Additionally, there are significant inequities in who is accessing PrEP. For example, despite accounting for 30% of new HIV diagnoses in 2023, only 3.1% of PrEP users in England are women3. Many people don't know that PrEP exists, don't consider themselves at risk, or aren't aware that NHS services like PrEP are free. Others may not feel comfortable going to a clinic or may face additional barriers, such as insecure immigration status or past negative experiences with healthcare…

LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma

James Park, CEO of LOTTE BIOLOGICS, stated, "This agreement serves as further validation of our competitiveness as a CDMO in the global antibody therapeutics market. We will continue striving not only to supply high-quality medicines that meet global standards, but also to become a company that delivers greater value to both our partners and patients." James Park, CEO of LOTTE BIOLOGICS, stated, "This agreement serves as further validation of our competitiveness as a CDMO in the…

MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®

Fractional Flow Reserve (FFR) is a commonly used technique in cardiac catheterization for assessing the extent of blood flow reduction in narrowed coronary arteries. Fractional Flow Reserve (FFR) is a commonly used technique in cardiac catheterization for assessing the extent of blood flow reduction in narrowed coronary arteries. Traditionally, this procedure involves administering a vasodilatory drug to dilate the blood vessels, followed by the insertion of a guidewire equipped with a...

Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the…

In 2024, approximately 97 million diagnosed cases were reported across the 7MM, with projections indicating a rise over the forecast period (2025–2034). The lifetime risk of symptomatic knee osteoarthritis is about 45–46%, while hip osteoarthritis risk is around 25%. In 2024, approximately97 milliondiagnosed cases were reported across the 7MM, with projections indicating a rise over the forecast period (2025–2034). The lifetime risk of symptomatic knee osteoarthritis is about45–46%,...

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in…

Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturingGLPG5101 demonstrated promising efficacy with durable CAR-T cell persistence and a favorable safety profile, including a 97% complete response rate, 100% MRD negativity in evaluable patients, sustained CAR-T expansion up to 21 months, and low rates of severe CRS and ICANS, with no deaths reported...

Polydeoxyribonudeotide (PDRN) Market to Surge with Anti-Aging & Regenerative…

The global market for Polydeoxyribonudeotide (PDRN) was valued at USD 72.1 million in the year 2024 and is projected to reach a revised size of USD 855 million by 2031, growing at a CAGR of 43.0% during the forecast period. The global market for Polydeoxyribonudeotide (PDRN) was valued atUSD 72.1 millionin the year 2024 and is projected to reach a revised size ofUSD 855 millionby 2031, growing at a CAGR of 43.0% during the forecast period. Claim Your Free Report: https://reports...

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – June 18, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 16, 2025, from Atlas Special…

Zealand Pharma announces positive topline results from 28-week Phase 1b trial…

Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideBody weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m 2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events...

Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic…

"The clinical relevance of Droplet IV's technology is clear," said John Lindskog, former executive of ConvaTec and Cimon Medical. "It fills a critical gap in IV medication safety and efficiency - a long-overdue solution for hospitals worldwide." "The clinical relevance of Droplet IV's technology is clear," saidJohn Lindskog, former executive of ConvaTec and Cimon Medical. "It fills a critical gap in IV medication safety and efficiency - a long-overdue solution…

Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is…

VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The…

Human Appeal announces summertime UK Comedy Tour

MANCHESTER, United Kingdom, June18, 2025(GLOBE NEWSWIRE) -- Following the roaring success of its annual winter Comedy Tour over the last decade, one of the UK’s leading humanitarian aid charities, Human Appeal, today announces its first ever summertime Comedy Tour.Taking place across three major UK cities - London, Manchester and Birmingham - Human Appeal’s summer Comedy Tour will feature some of the biggest names in the international comedy circuit: American actor and comic Omar...

Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75…

The Oligonucleotide Synthesis Market is expanding rapidly due to its critical role in drug development, genetic testing, and molecular diagnostics. Increasing R&D in genomics and rising investment in biotech innovations are making synthetic oligos a vital tool in precision healthcare and biotechnology workflows. The Oligonucleotide Synthesis Market is expanding rapidly due to its critical role in drug development, genetic testing, and molecular diagnostics. Increasing R&D in genomics…

Sterile Medical Packaging Market to Hit USD 44.6 Billion by 2029 | Key Drivers…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-16R15907/Global_and_India_Sterile_Medical_Packaging_Market Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-16R15907/Global_and_India_Sterile_Medical_Packaging_Market Major Factors Driving the Growth of Sterile Medical Packaging Market: The sterile medical packaging market is experiencing robust growth globally, driven by the rising need for infection control, regulatory...

Paradigm Therapeutics, Inc. Announces an Additional Investment by Eshelman…

MT PLEASANT, S.C., June 18, 2025 /PRNewswire/ -- Paradigm Therapeutics, Inc., a biopharmaceutical company, announces an additional investment by Eshelman Ventures, LLC of $12.6 million, bringing the total investment in 2025 for Paradigm Therapeutics to $25.1 Million. Dr. Eshelman will continue to serve as a strategic advisor for Paradigm. SD-101 is being developed as a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB) patients. The additional investment will be used to…

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of…

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorderBRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA populationOmaveloxolone is currently marketed under the brand name SKYCLARYS ®for the treatment of adults and adolescents aged 16 years and older affected by Friedreich ataxiaCAMBRIDGE, Mass., June18,...

"We must look ahead to create the future of the profession" says new CIMA…

John has spent a large part of his career in the National Health Service (NHS) in the UK, working for a range of NHS organisations, including the Department of Health, and has held Chief Finance Officer and Director of Finance roles for the last sixteen years. He is currently Chief Finance Officer – Tameside and Glossop IC NHS FT & Stockport NHS Foundation Trust and Deputy Chief Executive – Stockport NHS Foundation Trust. John has spent a large part of his career in the National Health…

Altri Comunicati